Neurocrine Biosciences, Inc. (NASDAQ:NBIX) had its price objective increased by BMO Capital Markets from $75.00 to $84.00 in a research note released on Friday morning. They currently have an outperform rating on the stock.
Other equities research analysts have also recently issued reports about the company. Oppenheimer Holdings, Inc. set a $60.00 price objective on Neurocrine Biosciences and gave the company a buy rating in a research report on Saturday, April 8th. Jefferies Group LLC increased their price objective on Neurocrine Biosciences from $65.00 to $67.00 and gave the company a buy rating in a research report on Monday, May 1st. Needham & Company LLC reissued a buy rating and issued a $58.00 price objective (down from $62.00) on shares of Neurocrine Biosciences in a research report on Wednesday, May 24th. J P Morgan Chase & Co set a $57.00 price objective on Neurocrine Biosciences and gave the company a buy rating in a research report on Wednesday, May 24th. Finally, Bank of America Corporation assumed coverage on Neurocrine Biosciences in a research report on Friday, May 5th. They issued a buy rating and a $70.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $68.25.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at 53.80 on Friday. The company’s market cap is $4.74 billion. The company has a 50 day moving average of $46.79 and a 200-day moving average of $46.23. Neurocrine Biosciences has a 52 week low of $37.35 and a 52 week high of $55.38.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.67) by $0.01. The firm had revenue of $6.34 million during the quarter, compared to the consensus estimate of $0.61 million. During the same period last year, the company earned ($0.46) earnings per share. On average, equities research analysts expect that Neurocrine Biosciences will post ($2.45) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “BMO Capital Markets Boosts Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Price Target to $84.00” was published by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.themarketsdaily.com/2017/08/08/bmo-capital-markets-boosts-neurocrine-biosciences-inc-nasdaqnbix-price-target-to-84-00.html.
In other Neurocrine Biosciences news, insider Dimitri E. Grigoriadis sold 10,000 shares of the stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $53.39, for a total transaction of $533,900.00. Following the completion of the transaction, the insider now directly owns 107,691 shares in the company, valued at $5,749,622.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Malcolm Lloyd-Smith sold 9,960 shares of the stock in a transaction on Friday, May 19th. The stock was sold at an average price of $53.63, for a total value of $534,154.80. Following the transaction, the insider now owns 17,997 shares of the company’s stock, valued at $965,179.11. The disclosure for this sale can be found here. Insiders have sold 28,694 shares of company stock valued at $1,504,755 over the last quarter. Corporate insiders own 4.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares in the last quarter. Wellington Management Group LLP raised its position in Neurocrine Biosciences by 554.4% in the first quarter. Wellington Management Group LLP now owns 2,407,376 shares of the company’s stock valued at $104,240,000 after buying an additional 2,039,509 shares in the last quarter. Janus Capital Management LLC raised its position in Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares in the last quarter. Goldman Sachs Group Inc. raised its position in Neurocrine Biosciences by 126.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,743,949 shares of the company’s stock valued at $75,513,000 after buying an additional 972,434 shares in the last quarter. Finally, MARSHALL WACE ASIA Ltd bought a new position in Neurocrine Biosciences during the first quarter valued at about $34,911,000. Hedge funds and other institutional investors own 96.48% of the company’s stock.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.